Infertility
Conditions
Keywords
ovarian stimulation, GnRH agonist, GnRH antagonist, hCG microdose, ICSI
Brief summary
The present prospective study was designed to compare the effects of administering a daily dose of gonadotrophin releasing hormone (GnRH) antagonist vs. an alternate-day dosage of GnRH agonist on ovarian response and in vitro fertilization (IVF) outcome in patients stimulated with recombinant follicle-stimulating hormone (FSH) and human chorionic gonadotrophin (hCG) microdose.
Detailed description
Inclusion criteria were as follows: women of good physical and mental health, under 37 years old, with regular menstrual cycles of 25-35 days, normal basal FSH and luteinizing hormone (LH) levels, body mass index (BMI) less than 30 kg/m2, presence of both ovaries and intact uterus, absence of polycystic ovaries, endometriosis, or gynaecological / medical disorders and a negative result in a screening for sexually transmitted diseases. No patient had received any hormone therapy for at least 60 days preceding the study. Eligible patients who agreed to participate were randomized in two treatment groups. Patients were allocated to a GnRH analogue treatment group according to a computer-generated randomization table.
Interventions
DRUGTriptorelin
Triptorelin (0.1 mg, Gonapeptyl® Daily; Ferring, Kiel, Germany) in alternate-days from Day 1 of the menstrual cycle until the day of hCG administration.
DRUGCetrorelix
When patients presented at least two follicles ≥ 14mm upon scan on days 7- 9, GnRH antagonist (cetrorelix, 0.25 mg/day, Cetrotide®; EMD Serono, Inc, Rockland, MA, USA) administration is started and continued until hCG administration.
Sponsors
Fertility - Assisted Fertilization Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
FEMALE
Age
No minimum to 35 Years
Healthy volunteers
No
Inclusion criteria
* women of good physical and mental health * under 37 years old, with regular menstrual cycles of 25-35 days * normal basal FSH and LH levels * BMI less than 30 kg/m2 * presence of both ovaries and intact uterus * absence of polycystic ovaries * endometriosis, or gynaecological / medical disorders and a negative result in a screening for sexually transmitted diseases * all patients signed a written informed consent form * no patient had received any hormone therapy for at least 60 days preceding the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cost of treatment | One month |
Secondary
| Measure | Time frame |
|---|---|
| Implantation and pregnancy rates | 2 months |
Countries
Brazil
Outcome results
None listed